Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America

BACKGROUND: Treatment options for the management of moderate to severe plaque psoriasis include phototherapy, oral systemic agents, and biologic therapy. Secukinumab, a fully human monoclonal antibody that selectively targets IL-17A, is the first IL-17 antagonist approved for this patient population...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, Kim A., Gooderham, Melinda, Beecker, Jennifer, Lynde, Charles W., Delorme, Isabelle, Dei-Cas, Ignacio, Albrecht, Lorne, Rampakakis, Emmanouil, Sampalis, John S., Vieira, Antonio, Hussein, Shamiza, Chambenoit, Olivier, Rihakova, Lenka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588885/
https://www.ncbi.nlm.nih.gov/pubmed/31226985
http://dx.doi.org/10.1186/s12895-019-0087-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6588885/
https://www.ncbi.nlm.nih.gov/pubmed/31226985
http://dx.doi.org/10.1186/s12895-019-0087-3

Ejemplares similares